HYPOMAGNESAEMIA
DEFINITION
A serum magnesium concentration below the normal range (typically 0.8
to 1.2 mmol/L, 1.6 to 2.4 mEq/L, 2.0 to 2.6 mg/dL).
TOXIC CAUSES
Alcoholism
Amphotericin
Aminoglycosides
Beta agonists
Cisplatin
Cyclosporin
Diuretics
Hydrofluoric acid
Laxatives
Pentamidine
Theophylline
NON-TOXIC CAUSES
Congenital renal magnesium wasting
Diabetes mellitus
Hyperparathyroidism
Hyperthyroidism
Inadequate magnesium intake
Pancreatitis
Primary hyperaldosteronism
Prolonged diarrhoea
Prolonged nasogastric suction
Renal transplantation
Total parenteral nutrition
CLINICAL FEATURES
The clinical features are non-specific, variable and not well
correlated with serum magnesium concentration. Initially, anorexia,
nausea, vomiting, lethargy and weakness may develop. The principal
symptoms of magnesium deficiency consist of paresthesiae, muscular
cramps, irritability, decreased attention span and mental confusion.
Physical findings reflect associated hypocalcaemia and may include
positive Trousseau's and Chvostek's signs, tremor, hyperreflexia,
peculiar movements of the fingers described as "athetoid tetany" and,
sometimes, convulsions.
Cardiac arrhythmias, disturbances of conduction, ventricular
fibrillation and cardiac arrest can occur in patients with coexisting
hypokalaemia.
DIFFERENTIAL DIAGNOSIS
Hypocalcaemia
Hypokalaemia
Neurologic disorders with increased deep tendon reflexes (e.g.
progressive primary muscular atrophy)
Seizures due to other causes
RELEVANT INVESTIGATIONS
Serum magnesium
Serum calcium, phosphorus
Serum sodium, potassium, chloride, bicarbonate
Renal function tests (urea, creatinine)
ECG
Arterial blood gas analysis
TREATMENT
In treating magnesium deficiency, it is important to detect and
correct any associated potassium and calcium deficiencies.
In mild magnesium deficiency, restoration of body stores occurs
quickly after providing a diet high in magnesium. In more severe
magnesium deficiency, parenteral administration of magnesium salts is
safe and effective but must be used cautiously in patients with renal
insufficiency. Initial treatment requires 8 to 12 g of intravenous
magnesium sulfate in divided doses over the first 24 hours, followed
by 4 to 5 g daily for 3 to 4 days. It is important to replete
magnesium stores in patients with hypomagnesaemia but not to provide
an excess.
Magnesium oxide is typically supplied as 600 mg tablets containing 30
mEq/L of magnesium per tablet. Several days of 4 to 6 tablets per day
should be sufficient to restore the deficit in most patients.
Administration of oral magnesium can cause diarrhoea.
CLINICAL COURSE AND MONITORING
The management of moderate-to-severe hypomagnesaemia should include
admission to hospital with monitoring of haemodynamic status,
neurologic status and serum electrolytes.
During replacement therapy, serum magnesium and deep tendon reflexes
should be monitored closely, especially in patients with renal
insufficiency. If the patient becomes weak or loses deep tendon
reflexes, stop the infusion immediately.
LONG-TERM COMPLICATIONS
None
AUTHOR(S)/REVIEWERS
Authors: Dr Tim Meredith and Dr Yeong-Liang Lin
Center for Clinical Toxicology
Vanderbilt University Medical Center
Nashville, USA.
Reviewers: Rio de Janeiro 9/97: J.N. Bernstein, E. Birtanov,
H. Hentschel, T.M. Meredith, Y. Ostapenko,
P. Pelclova, C.P. Snook, J. Szajewski
Birmingham 3/99: B. Groszek, H. Kupferschmidt,
N. Langford, K. Olson, J. Pronczuk.